The results of a study released Thursday (Feb. 4) shows that the tests of Cladribine in pill form has significantly reduced the relapses for people with relapsing Multiple Sclerosis.
The placebo-controlled study was published Thursday in The New England Journal of Medicine.
Cladribine was used for the 96-week trial for people who have been diagnosed with relapsing–remitting Multiple Sclerosis.
The 1,326 patients were randomly assigned one of two doses of the pill, given either 3.5 mg or 5.25 mg per kilogram of body weight. Others were given placebo.
The study monitored relapses over the 96 weeks.
The results are that:
"Among patients who received Cladribine tablets (either 3.5 mg or 5.25 mg per kilogram), there was a significantly lower annualized rate of relapse than in the placebo group."
The study concludes that treatment with the new medication significantly reduced relapse rates and the risk of disability progression.
...these other Examiners discussing MS:
- Gabrielle Sellers, the Denver Multiple Sclerosis Examiner
- Pamela Yelinek, the Houston Multiple Sclerosis Examiner
- Lori Friend, the Lima Multiple Sclerosis Examiner
- Miriam Franco, the Philadelphia Multiple Sclerosis Examiner
- Tom Scott's New York Disabilities Examiner, the MS stories
- Dev Meyers, the Canabis Revolution Examiner
- Mike Szymanski, the National Multiple Sclerosis Examiner
Comments
Thank you for the details. Good to know!
Got something to say?
Examiner.com is looking for writers, photographers, and videographers to join the fastest growing group of local insiders. If you are interested in growing your online rep apply to be an Examiner today!